The appointment of John Van Der Wielen as independent non-executive chairman marks a significant milestone for Orthocell Ltd. With his extensive experience in healthcare, wealth management, and corporate strategy, Van Der Wielen brings valuable expertise to the company’s leadership team. His track record of success in navigating diverse industries and driving international growth initiatives positions Orthocell for further development and commercialization of its regenerative medicine products.
Supported by an experienced senior advisory team and a cutting-edge portfolio of medical devices and cellular therapies, Orthocell is well-positioned to address unmet medical needs in the areas of tendon, cartilage, and soft tissue injuries. The company’s proprietary CellGro® platform offers promising prospects for improving patient outcomes and driving shareholder value.
The addition of Van Der Wielen follows the recent appointment of Dr. Ravi Thadhani, further strengthening the leadership capabilities of Orthocell. With a focus on accessing industry expertise and accelerating its growth trajectory, the company is poised to expand its presence in global markets and enhance its commercialization efforts.
As Orthocell advances towards the development and distribution of its innovative regenerative medicine solutions, it aims to translate local innovations into products that make a significant difference in clinical practice and patients’ lives. With the combined expertise of Van Der Wielen and the existing team, Orthocell is well-equipped to achieve its goals and establish itself as a leading player in the field of regenerative medicine.
Read More News: Click Here